Market Place
Sourcing Support
Aprea Therapeutics Doses Patient with HPV+ HNSCC in ACESOT Trial
31 Mar 2025 //
GLOBENEWSWIRE
Aprea Therapeutics Reports Q4 and Full Year 2024 Results
25 Mar 2025 //
GLOBENEWSWIRE
Aprea Therapeutics partners with MD Anderson on APR-1051 for HNSC
11 Mar 2025 //
GLOBENEWSWIRE
Aprea Therapeutics Announces IP Portfolio Evolution in Cancer DDR
05 Feb 2025 //
GLOBENEWSWIRE
Aprea Announces BID Dosing in ATRN-119 Trial to Optimize Outcomes
11 Dec 2024 //
GLOBENEWSWIRE
Aprea Therapeutics Q3 2024 Financial Results & Updates
07 Nov 2024 //
GLOBENEWSWIRE
Aprea Presents Findings on Oral WEE1 Inhibitor APR-1051
23 Oct 2024 //
GLOBENEWSWIRE
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
14 Oct 2024 //
GLOBENEWSWIRE
Aprea Announces Announces Presentations At EORTC-NCI-AACR Conference
10 Oct 2024 //
GLOBENEWSWIRE
Aprea Therapeutics Engages Philippe Pultar As Senior Medical Advisor
09 Oct 2024 //
GLOBENEWSWIRE
Aprea To Participate Lytham Partners Fall Investor Conference
25 Sep 2024 //
GLOBENEWSWIRE
Aprea Therapeutics To Present At H.C. Wainwright Conference
09 Sep 2024 //
GLOBENEWSWIRE
Aprea Therapeutics To Present At H.C. Wainwright Conference
28 Aug 2024 //
GLOBENEWSWIRE
Aprea Therapeutics Reports Q2 2024 Results And Provides Business Update
12 Aug 2024 //
GLOBENEWSWIRE
Aprea Therapeutics Hosts Virtual KOL Event on APR-1051 on June 24
21 Jun 2024 //
GLOBENEWSWIRE
Aprea Doses Patients With Oral WEE1 Inhibitor APR-1051
18 Jun 2024 //
PHARMABIZ
Aprea Therapeutics Doses First Patient In Phase 1 Trial For Oral WEE1 Inhibitor
17 Jun 2024 //
GLOBENEWSWIRE
Aprea: SRC Endorses 800mg ATRN-119 Dosing In Ongoing ABOYA-119 Trial
28 May 2024 //
GLOBENEWSWIRE
Aprea Therapeutics Reports Q1 2024 Results, Business Update
14 May 2024 //
GLOBENEWSWIRE
Aprea Therapeutics At RBC Healthcare Conference 2024
13 May 2024 //
GLOBENEWSWIRE
Aprea Appoints Mirza As CMO, Nasdaq Inducement Grants
02 May 2024 //
GLOBENEWSWIRE
Aprea Therapeutics Announces Presentations on APR-1051 and ATRN-119
10 Apr 2024 //
GLOBENEWSWIRE
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
26 Mar 2024 //
GLOBENEWSWIRE
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051
11 Mar 2024 //
GLOBENEWSWIRE
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
11 Mar 2024 //
GLOBENEWSWIRE
Aprea Therapeutics Announces Acceptance of Abstracts
05 Mar 2024 //
GLOBENEWSWIRE
Aprea Therapeutics Announces Submission of IND Application for APR-1051
06 Feb 2024 //
GLOBENEWSWIRE
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
30 Jan 2024 //
GLOBENEWSWIRE
Aprea Provides Corporate Update and Announces Development Plans for 2024
04 Jan 2024 //
GLOBENEWSWIRE
Aprea Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Aprea Therapeutics to Host a KOL Event on its SL and DDR Pathways
24 Oct 2023 //
GLOBENEWSWIRE
Aprea Unveils Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051
16 Oct 2023 //
GLOBENEWSWIRE
Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC
19 Sep 2023 //
GLOBENEWSWIRE
Aprea Announces Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051
11 Sep 2023 //
GLOBENEWSWIRE
Aprea to Present at the H.C. Wainwright 25th Annual Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors
24 Aug 2023 //
GLOBENEWSWIRE
Aprea Therapeutics Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference
14 Jun 2023 //
GLOBENEWSWIRE
Aprea Therapeutics to Present at BIO International Convention
30 May 2023 //
GLOBENEWSWIRE
Aprea Therapeutics Reports 1Q 2023 FYR Results & Provides Business Update
15 May 2023 //
GLOBENEWSWIRE
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
08 May 2023 //
GLOBENEWSWIRE
Aprea Therapeutics Reports 4Q and Reports Full 2022 FYR
30 Mar 2023 //
GLOBENEWSWIRE
Aprea Announces Presentation of Preclinical Data on Pipeline Programs
16 Mar 2023 //
GLOBENEWSWIRE
Aprea Therapeutics to Present at Oppenheimer 33rd Annual Healthcare Conference
07 Mar 2023 //
GLOBENEWSWIRE
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
01 Mar 2023 //
GLOBENEWSWIRE
Aprea Announces Closing of $5.5M Underwritten Public Offering of Common Stock
27 Feb 2023 //
GLOBENEWSWIRE
Aprea Therapeutics Announces Proposed Public Offering of Common Stock
22 Feb 2023 //
GLOBENEWSWIRE
Aprea Announces Pricing of $5.5M Underwritten Public Offering of Common Stock
22 Feb 2023 //
GLOBENEWSWIRE
Aprea Announces Phase II SBIR Award from the National Cancer Institute (NCI)
15 Feb 2023 //
GLOBENEWSWIRE
Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split
13 Feb 2023 //
GLOBENEWSWIRE
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer
30 Jan 2023 //
GLOBENEWSWIRE
Aprea Therapeutics to Participate in 6th Annual DDR Inhibitors Summit
19 Jan 2023 //
GLOBENEWSWIRE
Aprea Therapeutics begins subject dosing in solid tumours therapy trial
13 Jan 2023 //
CLINICAL TRIALS ARENA
Aprea Announces Dosing of First Patient in Phase 1/2a Trial of ATRN-119
11 Jan 2023 //
GLOBENEWSWIRE
Aprea Reports 3Q 2022 Financial Results & Update on Business Operations
09 Nov 2022 //
GLOBENEWSWIRE
Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin
22 Sep 2022 //
GLOBENEWSWIRE
Aprea Therapeutics to Participate in the 2022 H.C WGHC
08 Sep 2022 //
GLOBENEWSWIRE
Aprea Therapeutics Reports Q2 2022 Rusult & Provides Update
11 Aug 2022 //
GLOBENEWSWIRE
Aprea Announces Acquisition of Atrin and Reports Q1 2022 Financial Results
16 May 2022 //
GLOBENEWSWIRE
Aprea Tx Reports Q4 and FY 2021 Financial Results
15 Mar 2022 //
GLOBENEWSWIRE
